Thursday, April 04, 2024 2:48:54 PM
Bought in this morning...
Still holding...
GhosT
Recent CADL News
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 04/11/2024 01:00:00 PM
- Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma • GlobeNewswire Inc. • 03/28/2024 08:05:00 PM
- Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/28/2024 12:05:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:00:10 PM
- Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/13/2024 02:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 12:45:10 PM
- CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma • GlobeNewswire Inc. • 02/13/2024 12:30:00 PM
- Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts • GlobeNewswire Inc. • 02/05/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 01:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:30:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 01:30:08 PM
- Candel Therapeutics Shares Soar After FDA Fast Track of CAN-2409 • Dow Jones News • 12/12/2023 01:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 01:30:56 PM
- Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/30/2023 10:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/30/2023 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/30/2023 10:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 09:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 09:30:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 09:30:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 02:00:28 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM